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We examined how lipopolysaccharide (LPS) and interferon gamma (IFN-c), known to differentially
activate microglia, affect the expression of G protein-coupled receptor 55 (GPR55), a novel cannab-
inoid receptor. We found that GPR55 mRNA is signiﬁcantly expressed in both primary mouse
microglia and the BV-2 mouse microglial cell line, and that LPS down-regulates this message. Con-
versely, IFN-c slightly decreases GPR55 mRNA in primary microglia, while it upregulates this mes-
sage in BV-2 cells. Moreover, the GPR55 agonist, lysophosphatidylinositol, increases ERK
phosphorylation in BV-2 stimulated with IFN-c, in correlation with the increased amount of
GPR55 mRNA. Remarkably, these stimuli-induced changes in GPR55 expression are similar to those
observed with CB2-R, suggesting that both receptors might be involved in neuroinﬂammation and
that their expression is concomitantly controlled by the state of microglial activation.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction cells. Furthermore, various species of L-a-lysophosphatidylinositolTo date, two cannabinoid receptors belonging to the Gi/o pro-
tein-coupled receptor family have been identiﬁed. These include
the CB1 receptor (CB1-R), mostly located in neural cells, and the
CB2 receptor (CB2-R), predominantly expressed by immune cells
but also present in the CNS during neuroinﬂammatory states
[1]. However, there is growing evidence that a number of pharma-
cological and physiological effects produced by cannabinoids can-
not be fully explained by the actions of these two cannabinoid
receptor subtypes [2–5]. Recently, an orphan G protein-coupled
receptor 55 (GPR55) cloned several years ago [6], has emerged
as a candidate for mediating some of the non-CB1/non-CB2 re-
sponses induced by certain cannabinoids [5,7,8]. It has been re-
ported that several endogenous, as well as plant-derived and
synthetic cannabinoids, activate GTPcS binding [9,10] and in-
crease intracellular calcium [11,12] in GPR55-expressing HEK293chemical Societies. Published by E
ein-coupled receptor 55; IFN-
PS, lipopolysaccharide; qPCR,
artment, Weizmann Institute
1.
l).(LPI) including the arachidonoyl, stearoyl and palmitoyl species
elicit fast Ca2+ transients, as well as rapid phosphorylation of
the extracellular signal-regulated kinase (ERK) [13]. Thus, there
is broad agreement that LPI is a GPR55 agonist that could act as
its endogenous ligand [5,8,13].
Several cannabinoids were shown to possess anti-inﬂammatory
activities in various in vivo and in vitro inﬂammatory models
[1,14]. These effects are mostly due to cannabinoid binding to
the CB2-R, which is abundantly expressed by macrophages, den-
dritic cells and B cells [15]. In several cases the CB1-R has also been
implicated [1]. However, some of the anti-inﬂammatory actions of
cannabinoids are independent of CB1-R and CB2-R. Speciﬁcally,
studies using CB1-R/ and CB2-R/ mice support the existence
of additional cannabinoid targets in immune cells [14]. Thus,
numerous cannabinoids were shown to inhibit lipopolysaccharide
(LPS)-induced mRNA expression of several inﬂammatory cytokines
in rat microglia and this effect was not blocked by either CB1-R or
CB2-R antagonists [16]. Finally, studies on neuropathic and inﬂam-
matory pain employing GPR55/ mice indicate that GPR55 regu-
lates the production of various cytokines, thus resulting in
blunted inﬂammatory mechanical hyperalgesia [17].
Microglial cells are the resident innate immune cells in the
brain, and are responsible for controlling CNS infections andlsevier B.V. All rights reserved.
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cells has been implicated as an active contributor to the develop-
ment of several neurodegenerative diseases, including multiple
sclerosis and Alzheimer’s diseases [19,20]. Microglial cells can be
differentially activated by distinct stimuli that couple to indepen-
dent signaling pathways, such as the bacterial inﬂammatory endo-
toxin LPS and interferon gamma (IFN-c) [21].
While the presence of functional CB1-R in microglia is under
debate, CB2-R expression by microglia in culture is well accepted
[22–24]. The level of CB2-R expression can be up- or downregu-
lated by certain pathogens and cytokines [22,24–27]. Exposure
to LPS decreases the expression of CB2-R at both mRNA and
protein levels [22]. Conversely, IFN-c alone does not signiﬁcantly
affect CB2-R expression in primed microglia [22,26]. However,
treatment of the microglial cell line BV-2 with this cytokine sig-
niﬁcantly upregulates CB2-R expression [28]. It is therefore of
interest to study the regulation of GPR55 expression and its func-
tionality when microglia are activated by these two different
stimuli.
In this study, we report that primary mouse microglia and the
BV-2 microglial cell line express GPR55, and that this receptor is
differentially modulated by microglial activation. In parallel to
CB2-R, GPR55 mRNA expression is downregulated by LPS while
GPR55 mRNA is upregulated by IFN-c activation, but only in BV-
2 cells and not in microglial cells in primary culture.
2. Materials and methods
2.1. Materials
LPS from Escherichia coli serotype 055:B5 was from Sigma (St.
Louis, MO, USA). L-a-LPI from soybean was from Avanti Polar Lipids
Inc. (Alabaster, AL, USA). It contains primarily the palmitoyl and
stearoyl LPI molecular species. Primers for mouse CB1-R
(NM_009807), for mouse CB2-R (NM_009924) and for the mouse
homolog of GPR55 (Mm_Gm218; NM_001033290) were designed
as assay on demand by Qiagen (Hilden, Germany). The following
primers were used for mouse b-actin, forward: GAAATCGTGCGT
GACATCAAAG and reverse: AGGAAGGCTGGAAAAGAGCCT; and
for mouse b-microglobulin, forward: ATGGGAAGCCGAACATACTG
and reverse: CAGTCTCAGTGGGGGTGAAT.
2.2. Cell cultures
Mouse microglia in primary culture were prepared as previ-
ously described [29]. The BV-2 cell line, kindly provided by Prof.
E.J. Choi (Korea University, Seoul, Korea), was cultured in high glu-
cose DMEM (Gibco-BRL, Gaithersburg, MD, USA) supplemented
with 5% fetal calf serum (FCS), 100 U/ml penicillin and 100 lg/ml
streptomycin under a humidiﬁed 5% CO2 atmosphere at 37 C.
The N18TG2 mouse neuroblastoma cell line was grown as
described [4].
2.3. Isolation of total RNA and reverse transcription
RNA was extracted using the Versagene RNA puriﬁcation kit
(Gentra, Minneapolis, MN, USA) and RNA samples were reverse
transcribed using the QuantiTect Reverse Transcription Kit from
Qiagen (Hilden, Germany) including DNase treatment of contami-
nating genomic DNA.
2.4. Quantitative real time polymerase chain reaction (qPCR)
Expression of CB2-R and GPR55 mRNAs were determined by
qPCR, using b-actin or b-microglobulin as normalizing genes, as
previously described [30]. Normal and mock reversed transcribedsamples (in the absence of reverse transcriptase), as well as no
template controls (total mix without cDNA) were run for each of
the examined mRNA’s. qPCR reactions were subjected to an initial
step of 15 min at 95 C to activate the HotStar Taq DNA polymer-
ase, followed by 40 cycles consisting of 15 s at 94 C, 30 s at
60 C and 30 s at 72 C. Fluorescence was measured at the end of
each elongation step. Efﬁciency and the threshold cycle value Ct
(calculated from the exponential phase of each PCR sample) were
obtained using the Rotor-Gene software (Corbett Life Sciences,
Australia). Amounts of mRNAs were calculated and expressed in
relative units of SYBR Green ﬂuorescence, using the Pfafﬂ mathe-
matical model [31].
2.5. ERK phosphorylation
BV-2 cells were stimulated with recombinant IFN-c (Peprotech,
Rocky Hill, NY, USA) for 18 h under low serum conditions (0.1%
FCS). Cells were then incubated for 10 min with LPI and lysed in
RIPA buffer as described [32]. Protein concentration was deter-
mined by the Bradford assay (Bio-Rad, Hercules, CA, USA). Proteins
in lysates were separated by 8% SDS–PAGE, electrophoretically
transferred to nitrocellulose membranes and immunoblotted with
anti pERK or anti ERK1/2 from Sigma. Blots were developed with
horseradish peroxidase-conjugated antibodies (Jackson Immuno-
Research Laboratories, West Grove, PA, USA) and visualized using
the super-signal-enhanced chemiluminescence assay (Pierce,
Rockford, IL, USA).
2.6. Data analysis
Data were collected from three or more independent experi-
ments and are expressed as mean ± S.E.M. The statistical analysis
of the data was accomplished with one- or two-way factor analysis
of variance (ANOVA), followed by Bonferroni post hoc multiple
comparison test.
3. Results
3.1. Microglial cells express GPR55 receptors
In our ﬁrst set of experiments, we measured the level of CB1 and
CB2 receptor mRNA by qPCR analysis. We found a very low level of
CB1-R mRNA in both primary microglia (Ct of 36) and BV-2 cells (Ct
of 34; Fig. 1A). Indeed, when comparing these levels to the level of
CB1-R mRNA present in the murine neuroblastoma cell line
N18TG2 (which is known to contain high levels of CB1-R; [33])
we found that the neuroblastoma cell line (Ct of 26) expresses
approximately 10 000-fold higher levels than microglia. It is worth
noting that in BV-2 cells this very small amount of CB1-R mRNA
was not signiﬁcantly affected by either LPS or IFN-c treatments
(data not shown).
In contrast to the very low abundance of CB1-R, we found that
both CB2-R and GPR55 mRNAs were present at relatively high level
in unstimulated primary and in BV-2 microglial cells (Fig. 1B and
C). Speciﬁcally, qPCR analysis of CB2-R mRNA in BV-2 and primary
microglia resulted in Ct’s of 25.5 and 27, respectively, and of GPR55
mRNA in Ct’s of 28 and 31.5, respectively (Fig. 1B and C). Note that
the levels of GPR55 mRNA are only 8- and 30-fold lower than those
found for CB2-R mRNA.
3.2. LPS and IFN-c modulate GPR55 mRNA expression in primary
microglial cells
Microglia cells were treated with LPS (100 ng/ml) for 8 h or IFN-
c (200 U/ml) for 18 h. Total RNA was extracted, reverse-transcribed
and the cDNA subjected to qPCR analysis. The mRNA for b-micro-
Fig. 1. Cannabinoid receptors mRNA expression in microglial cells. Representative qPCR ampliﬁcation curves showing the different amounts of mRNAs for CB1-R in N18TG2,
primary microglia (MG) and BV-2 cells (A), and for CB2-R and GPR55 in MG (B) and BV-2 cells (C).
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used for data normalization.
These treatments signiﬁcantly affected the amount of GPR55
mRNA [F(2, 8) = 62.2; P < 0.01]. Speciﬁcally, LPS reduced GPR55
mRNA levels by 87% (P < 0.01), whereas IFN-c induced a lower,
but signiﬁcant, reduction of 45% in GPR55 mRNA (P < 0.01;
Fig. 2). Remarkably, the expression of CB2-R mRNA was concom-
mittantly affected by both treatments [F(2, 8) = 109.8; P < 0.01],
since LPS reduced CB2-R mRNA expression by 90% (P < 0.01) and
IFN-c by 25% (P < 0.05; Fig. 2).3.3. LPS downregulates and IFN-c upregulates GPR55 mRNA
expression levels in BV-2 cells
We then compared the regulation of GPR55 and CB2-R mRNA
expression in BV-2 cells after treatment with LPS and IFN-c. The
cells were treated with either LPS (1, 10 and 100 ng/ml) for 4
and 8 h or IFN-c (50, 100 and 200 U/ml) for 8 and 18 h. The amount
of GPR55 mRNA was markedly downregulated after 4 and 8 h of
LPS treatment. This downregulation was dose- [F(1, 27) = 132;
P < 0.01] but not time-dependent [F(1, 27) = 0.09; P = 0.8]
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Fig. 2. Effects of LPS and IFN-c on cannabinoid receptor mRNA levels in primary
microglial cells. Primary microglial cells (MG) were incubated with LPS (100 ng/ml)
for 8 h or with IFN-c (200 U/ml) for 18 h and the relative levels of CB2-R and GPR55
mRNA’s determined by qPCR. mRNA levels for both genes were normalized against
b-microglobulin mRNA levels and are presented as fold increase relative to control.
Values correspond to the average ± S.D. of at least three independent experiments
(*P < 0.05; **P < 0.01; one-way ANOVA followed by the Bonferroni post hoc test).
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Fig. 3. Effect of LPS on cannabinoid receptor mRNA levels in BV-2 cells. Cells were
incubated with LPS (1, 10, 100 ng/ml) for 4 h or 8 h (A), or with 10 ng/ml LPS for the
indicated times (B), and the levels of CB2-R and GPR55 mRNA’s determined by qPCR
(*P < 0.05; **P < 0.01; one- and two-way ANOVA followed by the Bonferroni post hoc
test).
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Fig. 4. Effect of IFN-c on the expression of cannabinoid receptor mRNAs in BV-2
cells. Cells were incubated with IFN-c (50, 100 and 200 U/ml) for 8 h or 18 h and the
levels of CB2-R and GPR55 mRNA’s determined by qPCR (
*P < 0.05; **P < 0.01; two-
way ANOVA followed by the Bonferroni post hoc test).
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(P < 0.01) at 8 h with 100 ng/ml LPS. A lower, but signiﬁcant, reduc-
tion of 70% in GPR55 mRNA was observed with concentrations as
low as 1 ng/ml of LPS after either 4 h or 8 h incubation (P < 0.01).Again, a concommittant downregulation of CB2-R was found since
1 ng/ml LPS reduced this receptor’s mRNA by 62% at 4 h and at 8 h
and 100 ng/ml LPS reduced its mRNA by 89% (P < 0.01; Fig. 3A).
Note that the LPS-induced downregulation of GPR55 mRNA was al-
ready maximal after 4 h of treatment. These results prompted us to
study the time dependency of LPS-induced downregulation of
mRNA for both receptors in more detail. Fig. 3B shows the expres-
sion of CB2-R and GPR55 mRNAs as a function of time in the pres-
ence of 10 ng/ml LPS. It shows that the reduction in CB2-R mRNA
expression is faster than that of GPR55, with a 50% decrease in
CB2-R mRNA expression after 1 h, while more than 2 h were
needed to reach the same reduction in GPR55 mRNA levels.
Conversely, the addition of IFN-c resulted in a dose-
[F(3, 27) = 21.4; P < 0.01] and time-dependent [F(1, 27) = 5.5;
P < 0.05] upregulation of the expression of GPR55 mRNA. This
upregulation reached a 3-fold increase after 8 h treatment
(P < 0.01) and 4.5-fold increase after 18 h treatment (P < 0.01) with
200 U/ml IFN-c (Fig. 4). The expression of CB2-R mRNA was simi-
larly upregulated in a dose- [F(3, 31) = 36; P < 0.01] and time-
dependent [F(1, 31) = 41; P < 0.01] manner and reached a 4-fold in-
crease (P < 0.01) after 8 h and a 6-fold increase (P < 0.01) after 18 h
with 200 U/ml IFN-c.
3.4. LPI induces a dose-dependent phosphorylation of ERK1/2 in
GPR55-upregulated BV-2 cells
BV-2 cells were incubated for 18 h in the presence or absence of
200 U/ml IFN-c. LPI was then added for 10 min at 1, 5 and 10 lM,
and the level of ERK1/2 phosphorylation determined by Western
blotting analysis. Fig. 5 shows that LPI stimulates ERK phosphory-
lation. While in the absence of IFN-c the stimulation by LPI was
relatively small, in IFN-c-stimulated cells LPI induced a marked
dose-dependent phosphorylation of ERK. Both ERK1 and ERK2
were similarly phosphorylated. It is interesting to note that IFN-c
by itself (in the absence of LPI) also induced ERK1/2 phosphoryla-
tion, as previously shown in RAW 264.7 cells [34]. These effects of
IFN-c and LPI were signiﬁcant since two-way ANOVA analysis of
these data resulted in F(1, 27) = 10.12; P < 0.01 for IFN-c and
F(3, 23) = 62.1; P < 0.01 for LPI dose. Moreover, IFN-c treatment
and LPI dose showed a signiﬁcant statistical interaction
[F(3, 27) = 3.11; P = 0.05].
In a parallel experiment, BV-2 cells were incubated for 4 h in the
presence or absence of 100 ng/ml LPS, followed by 10 min incuba-
tion with or without LPI. However, LPS by itself induced a very
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Fig. 5. Effect of LPI on ERK1/2 phosphorylation in BV-2 cells. Cells in 0.1% FCS were
incubated for 18 h in the presence or absence of 200 U/ml IFN-c, followed by
10 min incubation with or without LPI (1, 5 and 10 lM). (A) Western blots of ERK1/
2 versus total ERK. (B) Levels of pERK1/2 expressed as fold induction versus control
(*P < 0.05; **P < 0.01; two-way ANOVA followed by the Bonferroni post hoc test).
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nation of the effect of reducing GPR55 expression on ERK activity
(data not shown).
4. Discussion
Recent studies show that various cannabinoids applied to
GPR55-transfected HEK293 cells stimulate GTPcS binding as well
as increase the release of calcium from IP3 receptor-dependent
stores [10,12]. These results led to the notion that GPR55 is a novel
cannabinoid receptor subtype, even though it is only 13.5% identi-
cal to CB1-R and 14.4% to CB2-R [7]. GPR55 is expressed in many
mammalian tissues including several brain regions [6,7], however
its physiological roles are largely unknown.
Here we show that GPR55 mRNA is expressed in both mouse
primary microglia cells and in the murine microglial cell line
BV-2, and conﬁrm the presence of CB2-R mRNAs in these cells.
Moreover, we found that their pattern of regulation is very simi-
lar. In addition, we demonstrate that following IFN-c treatment,
the effect of the GPR55 agonist, LPI, on ERK phosphorylation is in-
creased. This is in correlation with the increased amount of
GPR55 mRNA in BV-2 cells that we found. This differential mod-
ulation of CB2-R and GPR55 expressions by various stimuli during
BV-2 microglial activation suggests that similar to CB2-R, GPR55
could be involved in modulating inﬂammatory signaling and that
in turn BV-2 cell activation might be affected by both receptors.
Indeed, it has been recently reported that GPR55 signaling inﬂu-
ences the regulation of certain cytokines that contribute to hyper-
algesia [17].
There is increasing evidence that the CB2-R in microglia plays a
functional role in CNS immunity and anti-inﬂammatory effects
[24,27]. In agreement with previous reports, we show that various
stimuli affect CB2-R mRNA expression in microglia [22,26]. The fact
that treatment of microglial cells with IFN-c or LPS leads to differ-
ent states of activation and to different properties of the activated
cells agrees with the ‘‘in vitro model of multi-step activation”.
According to this model, microglial cells reach the primed state
(antigen presentation) in response to IFN-c treatment, which is fol-lowed by the fully activated state (cytotoxic stage) after exposure
to LPS [22,27]. We found that contrary to the signiﬁcant upregula-
tion in the expression of CB2-R and GPR55 in BV-2 cells, in primary
microglial cells IFN-c treatment leads to a small, but signiﬁcant,
downregulation of the mRNA levels for both receptors. This obser-
vation is similar to previous results on the regulation of CB2-R
mRNA by IFN-c [22,26,28]. This difference between BV-2 and pri-
mary microglia could be due to the fact that the two preparations
reﬂect different states of microglial activation. Microglial cells in
primary cultures are intrinsically activated or ‘‘primed” because
of the procedure involved in transferring these cells into culture
[35] and IFN-c increases the expression of CB2-R only in combina-
tion with GM-CSF [22,26]. Whereas in BV-2 cells, which intrinsi-
cally exhibit high rates of proliferation, activation with IFN-c is
sufﬁcient to increase the expression levels of both CB2-R and
GPR55 without the need of co-stimulation by the growth factor
GM-CSF.
Our results show that CB1-R mRNA in microglia cells is present
at relatively low levels, and this independently of the states of cell
activation. This result is in agreement with the ﬁnding that CB1-R
was not detected in the murine macrophage-like cell line
RAW264.7 regardless of cell activation state and was found in neo-
natal rat microglia at very low levels [22,23].
In conclusion, our results show that GPR55 is expressed by
microglia and suggest that this novel cannabinoid receptor may
participate in regulating inﬂammatory responses depending on
the microglial speciﬁc activation state.
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